MiniMed touts ‘excellent start’ to fiscal year

NORTHRIDGE, Calif. – MiniMed reported global net sales of $843 million for the first quarter of fiscal year 2027, growing 17% as reported and 16% organic. The company says U.S. net sales were $240 million, growing 13% as reported and organic. “MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline," said MiniMed CEO Que Dallara. "The U.S. launch of MiniMed Flex is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value." In connection with its financial results, MiniMed announced:

• MiniMed Fit patch pump submitted to U.S. FDA, ahead of fall target; full U.S. launch expected summer 2027
• MiniMed Flex received CE Mark, well ahead of calendar 2026 year-end target; commercial launch expected in November
• Vivera fully-closed loop algorithm U.S. pivotal trial for T1 and T2 enrollment complete; on track for second half calendar 2027 U.S. launch
• Next-gen MiniMed extended wear sensor U.S. IDE approved; expect first enrollment in pivotal trial this fall

For the full fiscal year 2027 ending April 30, 2027, MiniMed expects:

• Organic revenue growth of approximately 10.5%, which includes the approximate 1% to 1.5% benefit from the extra week in Q1 FY27, a raise from the prior guidance of approximately 10%
• Adjusted EBITDA margin of approximately 16%, reaffirming prior guidance